Pharmaceutical Technology

JUNE 21, 2023

CSL announced the first patient with haemophilia B has been treated with its recently approved gene therapy Hemgenix (etranacogene dezaparvovec). Hemgenix is the first and only gene therapy approved for haemophilia B. This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).

FDA 98

FDA 98

European Pharmaceutical Review

NOVEMBER 10, 2022

Advanced light microscopy techniques have emerged as a foundation of biomedical research, capable of visualising cellular functions at very high resolution whilst being minimally invasive to the cells or tissues of interest. Dr Lorna Fitzpatrick is Lead Scientist – Cell and Molecular Engineering, Medicines Discovery Catapult.

Labelling 95

Labelling Compounding 95

European Pharmaceutical Review

DECEMBER 27, 2023

Chimeric antigen receptor (CAR) T cells are the first example of a “living drug”. 1 Following in vitro production from T cells collected from a patient’s leukapheresis procedure, the CAR T cells are infused back into the patient’s blood, where they proliferate and expand. This is variable and to some extent unpredictable.

Adverse Reactions 82

Adverse Reactions Immunization Medical Schools Chemotherapy 82

The Physician Pharmacist

SEPTEMBER 14, 2023

you know, taking general science courses or four years, we were taking pharmaceutics and all these, these clinical body system pharmaceutical courses with high level biology, chemistry, so in they don't really give you a lot too much slack. So I don't know why we have to look at, you know, cells in a petri dish. O l@liberty.edu.

Medical Schools 52

Medical Schools Hospitals Communication Patient Care 52